10.1002/ejoc.201900498
European Journal of Organic Chemistry
FULL PAPER
[3]
a) J. A. Bull, R. A. Croft, O. A. Davis, R. Doran, K. F. Morgan, Chem. Rev.
2016, 116, 12150–12233. b) G. Wuitschik, E. M. Carreira, B. Wagner, H.
Fischer, I. Parrilla, F. Schuler, M. Rogers-Evans, K. Müller, J. Med. Chem.
2010, 53, 3227–3246. c) E. M. Carreira, T. C. Fessard, Chem. Rev. 2014,
114, 8257–8322. d) A. A. Kirichok, I. Shton, M. Kliachyna, I. Pishel, P. K.
Mykhailiuk, Angew. Chem. Int. Ed. 2017, 56, 8865–8869.
Torre, B. N. Diaz Buezo, J. E. Fritz, W. G. Holloway, J. E. J. Matt, C. H.
Mitch, C. Pegregal-Tercero, S. J. Quimby, M. G. Siegel, D. R. Smith, R.
D. Stucky, K. Takeuchi, E. M. Thomas, C. N. Wolfe, Diaryl ethers as
opiod receptor antagonist. PCT Int. Appl. WO2004026305A1, Apr 01,
2004. d) J. E. Macor, K. E. Carlson, Co-administration of melanocortin
receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-
AMP associated disorders. PCT Int. Appl. WO02069905A2, Sept 12,
2002. For further examples of 3,3-diarylazetidines see ref 25.
[12] a) A. Bartolozzi, Z. Chen, J. A. Dines, H. Y. Lo, P. L. Loke, A. Olague, D.
Riether, H. Tye, L. Wu, R. M. Zindell, Heterocyclic compounds as
inhibitors of leukotriene production. PCT Int. Appl. WO2013116182A1,
Aug 08, 2013. b) L. Chu, H. M. Armstrong, L. L. Chang, A. F. Cheng, L.
Colwell, J. Cui, J. Evans, A. Galka, M. T. Goulet, N. Hayes, et al., Bioorg.
Med. Chem. Lett. 2012, 22, 4133–4138.
[4]
For examples of methods to form heterocyclic derivatives with varied
aromatic substituents, see: a) C. T. Vo, J. W. Bode, J. Org. Chem. 2014,
79, 2809–2815. For recent examples, see: b) A. J. Boddy, D. P. Affron,
C. J. Cordier, E. L. Rivers, A. C. Spivey, J. A. Bull, Angew. Chem. Int. Ed.
2019, 58, 1458–1462. c) D. Antermite, D. P. Affron, J. A. Bull, Org. Lett.
2018, 20, 3948–3952. d) D. P. Affron, J. A. Bull, Eur. J. Org. Chem. 2016,
2016, 139–149. e) W.-Y. Siau, J. W. Bode, J. Am. Chem. Soc. 2014, 136,
17726–17729. f) For cyclobutane CH arylation, see: W. R. Gutekunst, P.
S. Baran, J. Am. Chem. Soc. 2011, 133, 19076–19079.
[13] M. C. Hansen, X. Verdaguer, S. L. Buchwald, J. Org. Chem. 1998, 63,
2360–2361.
[5]
[6]
[7]
K. Kuwata, T. Kimura, J. Muto, Prion protein structure transformation
inhibitor and utilization of same. PCT Int. Appl. WO2010131717A1, Nov
18, 2010.
[14] D. R. Arnold, B. J. Fahie, L. J. Lamont, J. Wierzchowski, K. M. Young,
Can. J. Chem. 1987, 65, 2734–2743.
B. Fauber, E. Gancia, T. Duwahetty, D. Vesey, P. Winship, O. Rene, Aryl
sultam derivatives as RORc modulators. PCT Int. Appl.
WO2017005900A1, Jan 12, 2017.
[15] For selected examples of hydroamination, see: a) X. Han, R. A.
Widenhoefer, Angew. Chem. Int. Ed. 2006, 45, 1747–1749. b) J. Zhang,
C.-G. Yang, C. He, J. Am. Chem. Soc. 2006, 128, 1798–1799. c) E.
Bernoud, P. Oulié, R. Guillot, M. Mellah, J. Hannedouche, Angew. Chem.
Int. Ed. 2014, 53, 4930–4934. d) C. Lepori, P. Gómez-Orellana, A.
Ouharzoune, R. Guillot, A. Lledós, G. Ujaque, J. Hannedouche, ACS
Catal. 2018, 8, 4446–4451.
a) K. Cho, M. Ando, K. Kobayashi, H. Miyazoe, T. Tsujino, S. Ito, T.
Suzuki, T. Tanaka, S. Tokita, N. Sato, Bioorg. Med. Chem. Lett. 2009,
19, 4781–4785. b) S. Liras, S. F. McHardy, M. P. Allen, B. E. Segelstein,
S. D. Heck, D. K. Bryce, A. W. Schmidt, M. Vanase-Frawley, E. Callegari,
S. McLean, Bioorg. Med. Chem. Lett. 2010, 20, 503–507. c) R. Olsson,
L. Hyldtoft, F. Piu, M. Gustaffsson, Compounds with activity at estrogen
receptors. PCT Int. Appl. WO2007056500A3, Sep 20, 2007. d) A. Banka,
J. R. Bencsik, J. F. Blake, M. F. Hentemann, N. C. Kallan, J. Liang, I. S.
Mitchell, S. T. Schlachter, E. M. Wallace, R. Xu, T. P. Tang, 5H-
Cyclopenta[D]pyrimidines as AKT protein kinase inhibitors. PCT Int. Appl.
WO2009089462A1, Jul 16, 2009. e) D. K. Donald, A. S. R. Jennings, N.
C. Ray, F. Roussel, J. M. Sutton, P. Tisselli, M. Wilson, Cyclic amine
derivatives having beta2 adrenergic receptor agonist and muscarinic
receptor antagonist activity. PCT Int. Appl. WO2011048409A1, Apr 28,
2011. f) I. Egle, M. Isaac, R. Urbanek, F. M. Mclaren, S. B. Walsh, G. B.
Steelman, D. G. Brown, D. Nugiel, D. W. Chen, A. Slassi, F. Ma, Bicyclic
benzimidazole compounds and their use as metabotropic glutamate
receptor potentiators. PCT Int. Appl. WO2007115077A3, Dec 27, 2007.
g) D. Neuser, J.-P. Stasch, M. Witteler, W. Kuhn, M. Gerlach, P. Jutzi, H.
Przuntek, Eur. J. Pharmacol. 1983, 87, 315–318.
[16] a) N. Sperber, R. Fricano, J. Am. Chem. Soc. 1953, 75, 2986–2988. b)
A. R. Katritzky, S. K. Nair, R. M. Witek, S. M. Hutchins, Arkivoc 2003,
2003, 9–18.
[17] For use of FeCl3 see a) ref 12a b) F. Piu, D. W. Gil, R. Olsson, M.
Gustafsson, L. Hyldtoft, K. F. Siemasko, M. E. Stern, Compounds with
activity at estrogen receptors. PCT Int. Appl. WO2008033894A2, Mar 20,
2008. For use of TfOH, see c) M. G. Bell, K. Gavardinas, D. L. Gernert,
T. A. Grese, P. K. Jadhav, P. A. Lander, M. I. Steinberg, Indole-derivative
modulators of steroid hormone nuclear receptors. PCT Int. Appl.
WO2004067529, Aug 12, 2004.
[18] Use of sulfuric acid: a) F. Diederich, K. Dick, D. Griebel Chem. Ber., 1985,
118, 3588–3619. Use of TfOH: b) D. A. Klumpp, M. Garza, A. Jones, S.
Mendoza, J. Org. Chem. 1999, 64, 6702–6705. Use of HCl: see ref 8b.
Use of AlCl3: See refs 9b and 10; See ref 10a where also applied to 3,3-
diarylazetidines and 3,3-diarylpyrrolidines.
[19] D. R. Carcanague, F. Diederich, Angew. Chem., Int. Ed. Engl. 1990, 29,
769–771. See also ref 17b.
[8]
[9]
4,4-Diarylpiperidines have also found significant application in
supramolecular chemistry. a) F. Diederich, Angew. Chem., Int. Ed. Engl.
1988, 27, 362–386. b) H. Adams, C. A. Hunter, K. R. Lawson, J. Perkins,
S. E. Spey, C. J. Urch, J. M. Sanderson, Chem. Eur. J. 2001, 7, 4863–
4878.
[20] For selected additional examples, see: a) V. Mallardo, R. Rizzi, F. C.
Sassone, R. Mansueto, F. M. Perna, A. Salomone and V. Capriati, Chem.
Commun., 2014, 50, 8655–8658. b) B. Drouillat, E. D’Aboville, F.
Bourdreux, F. Couty, Eur. J. Org. Chem. 2014, 2014, 1103–1109. c) L.
R. E. Pantaine, J. A. Milligan, J. K. Matsui, C. B. Kelly, G. A. Molander,
Org. Lett. 2019, 21, 2317–2321.
a) R. Boer, A. Grassegger, C. Schudt, H. Glossmann, Eur. J. Pharmacol.
Mol. Pharmacol. 1989, 172, 131–145. b) J. M. Wetzel, S. W. Miao, C.
Forray, L. A. Borden, T. A. Branchek, C. Gluchowski, J. Med. Chem.
1995, 38, 1579–1581. c) W. C. Wong, B. Lagu, D. Nagarathnam, M. R.
Marzabadi, C. Gluchowski, Dihydropyrimidines and uses thereof. PCT
Int. Appl. WO9851311A2, Nov 19, 1998.
[21] For recent reviews on catalytic C–O activation, see: a) M. Dryzhakov, E.
Richmond, J. Moran, Synthesis 2016, 48, 935–959. b) M. Rueping, B. J.
Nachtsheim, Beilstein J. Org. Chem. 2010, 6, DOI: 10.3762/bjoc.6.6. c)
L. Chen, X.-P. Yin, C.-H. Wang, J. Zhou, Org. Biomol. Chem. 2014, 12,
6033–6048.
[10] a) S. J. Woodhead, R. Downham, C. Hamlett, S. Howard, H. F. Sore, M.
L. Verdonk, D. W. Walker, R. W. A. Luke, Aryl-alkylamines and
heteroaryl-alkylamines as protein kinase inhibitors. PCT Int. Appl.
WO2006136830A1, Dec 28, 2006. For further studies on the
diarylpiperidine series, see: b) A. Donald, T. McHardy, M. G. Rowlands,
L.-J. K. Hunter, T. G. Davies, V. Berdini, R. G. Boyle, G. W. Aherne, M.
D. Garrett, I. Collins, J. Med. Chem. 2007, 50, 2289–2292. c) G. Saxty,
S. J. Woodhead, V. Berdini, T. G. Davies, M. L. Verdonk, P. G. Wyatt, R.
G. Boyle, D. Barford, R. Downham, M. D. Garrett, R. A. Carr, J. Med.
Chem. 2007, 50, 2293–2296.
[22] For selected leading references, see: a) M. Niggemann, M. J. Meel,
Angew. Chem. Int. Ed. 2010, 49, 3684–3687. b) M. Niggemann, N. Bisek,
Chem. Eur. J. 2010, 16, 11246–11249. c) S. Haubenreisser, M.
Niggemann, Adv. Synth. Catal. 2011, 353, 469–474. d) M. Dryzhakov, M.
Hellal, E. Wolf, F. C. Falk, J. Moran, J. Am. Chem. Soc. 2015, 137, 9555-
9558. e) S. Estopiñá-Durán, L. J. Donnelly, E. B. Mclean, B. M. Hockin,
A. M. Z. Slawin, J. E. Taylor, Chem. Eur. J. 2019, 25, 3950–3956. f) V.
D. Vuković, E. Richmond, E. Wolf, J. Moran, Angew. Chem. Int. Ed. 2017,
56, 3085–3089.
[11] For examples of 3,3-diarylpyrrolidines see: a) S. Peddi, B. L. Roth, R. A.
Glennon, R. B. Westkaemper, Bioorg. Med. Chem. Lett. 2004, 14, 2279–
2283. b) C. Chen, B. Stearns, T. Hu, N. Anker, A. Santini, J. M. Arruda,
B. T. Campbell, P. Datta, J. Aiyar, B. Munoz, Bioorg. Med. Chem. Lett.
2006, 16, 746–749. c) M.-J. Blanco-Pillado, M. D. Chappell, M. G. De La
[23] a) R. A. Croft, J. J. Mousseau, C. Choi, J. A. Bull, Chem. Eur. J. 2016,
22, 16271–16276. b) R. A. Croft, J. J. Mousseau, C. Choi, J. A. Bull,
Tetrahedron 2018, 74, 5427–5435.
[24] R. A. Croft, J. J. Mousseau, C. Choi, J. A. Bull, Chem. Eur. J. 2018, 24,
818–821.
This article is protected by copyright. All rights reserved.